The medical management of prostate cancer: a multidisciplinary team approach. (Q36586934)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

The medical management of prostate cancer: a multidisciplinary team approach (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

William K. Oh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

8

Tomasz M Beer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1

Cora N Sternberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

7

Alexandre Zlotta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Sergio Bracarda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Joaquim Bellmunt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Haluk Ozen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Stephane Oudard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Michael Rauchenwald

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Iwona Skoneczna

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Markus M Borner

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

John M Fitzpatrick

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

6 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

22-27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16956362%20AND%20SRC:MED&resulttype=core&format=json

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Management of advanced prostate cancer after first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Satraplatin in the treatment of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Epothilones and the next generation of phase III trials for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X

Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06477.X